Phil Vick­ers talks new role as head of Long­wood’s Solu af­ter Faze shut­down; Re­gen­eron CFO to re­tire in Feb­ru­ary

Phil Vick­ers start­ed last week as pres­i­dent and CEO of Solu Ther­a­peu­tics, a Long­wood Fund start­up de­vel­op­ing small mol­e­cule-an­ti­body chimeras. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.